Evidence map›Paper›PMID 38523518›Full record

ReviewCurrent pharmaceutical design2024

The Role of Traditional Chinese Medicine and Chinese Pharmacopoeia in the Evaluation and Treatment of COVID-19.

Amin Gasmi, Sadaf Noor, Maryam Dadar, Yuliya Semenova, Alain Menzel, Asma Gasmi Benahmed, Geir Bjørklund

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical design, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 5 countries.

Amin GasmiSociété Francophone de Nutrithérapie et de Nutrigénétique Appliquée, Villeurbanne, France.
Sadaf NoorInstitute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan, Pakistan.
Maryam DadarCONEM Iran Microbiology Research Group, Tehran, Iran.
Yuliya SemenovaSchool of Medicine, Nazarbayev University, Astana, Kazakhstan.
Alain MenzelLaboratoires Réunis, Junglinster, Luxembourg.
Asma Gasmi BenahmedAcadémie Internationale de Médecine Dentaire Intégrative, Paris, France.
Geir BjørklundCouncil for Nutritional and Environmental Medicine (CONEM), Mo i Rana, Norway.
Bahauddin Zakariya University · PKChemistry and Chemical Engineering Research Center of Iran · IRNazarbayev University · KZSociété Francophone d’Arthroscopie · FRThe Research Council of Norway · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The epidemic prompted by COVID-19 continues to spread, causing a great risk to the general population's safety and health. There are still no drugs capable of curing it. Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) are the two other diseases caused by coronaviruses. Traditional Chinese Medicine (TCM) showed benefits in treating SARS and MERS by preventing the disease early, substantially mitigating symptoms, shortening the treatment period, and minimizing risks and adverse reactions caused by hormone therapy. Although several vaccines have been developed and are being used for the treatment of COVID-19, existing vaccines cannot provide complete protection against the virus due to the rapid evolution and mutation of the virus, as mutated viral epitopes evade the vaccine's target and decrease the efficacy of vaccines. Thus, there is a need to develop alternative options. TCM has demonstrated positive effects in the treatment of COVID-19. Previous research studies on TCM showed broad-spectrum antiviral activity, offering a range of possibilities for their potential use against COVID-19. This study shed some light on common TCM used for SARS and MERS outbreaks and their effective use for COVID-19 management. This study provides new insights into COVID-19 drug discovery.

Indexed as

Antiviral AgentsCOVID-19COVID-19 Drug TreatmentDrugs, Chinese HerbalMedicine, Chinese TraditionalSARS-CoV-2HumansPharmacopoeias as TopicAntiviral AgentsDrugs, Chinese HerbalCOVID-19herbsmiddle East respiratory syndrome.pneumoniasevere acute respiratory syndrometraditional Chinese medicines

Identifiers

PMID38523518
OpenAlexW4393157626

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.